Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy

Authors:	Wei Liu Wenyang Huang Min Wang Rui Lv Jian Li Ying Wang Shuhui Deng Shuhua Yi Hong Liu Qing Rao Yingxi Xu Lulu Lv Lugui Qiu Dehui Zou Jianxiang Wang

Affiliation:	1. State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;2. State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China These authors contributed equally to this work.;3. Juventas Cell Therapy Ltd., Tianjin, China

Abstract:

Keywords:	hepatitis B reactivation anti-CD19 CAR T cell B-cell lymphoma chronic HBV infection resolved HBV infection